If successful, these trials will enable early initiation of highly effective CFTR modulator therapy, which has the potential to preserve pulmonary function at near-normal levels, and to arrest the annual decline in lung function that is currently characteristic of CF. This evidence concerns the gene CFTR and cystic fibrosis.